本帖最后由 老马 于 2012-1-13 21:20 编辑 + h" V0 i4 Y4 D7 f
2 s5 N$ b: y' U1 ]# J }! o* J爱必妥和阿瓦斯丁的比较
3 O# J- F) r, c: E/ d
/ w5 ]. Z3 p+ b) E' s6 W9 _
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/4 E n5 T; n% C
" q& }5 k+ ~1 K
+ v8 Y/ E+ H0 Q* ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' \0 q, t ?" z y" l' _; @$ b
==================================================
6 o3 ]6 `! k* ^7 K/ F7 z$ E- WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' b* p0 I+ y& S! G% G; ~Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.8 w+ o3 h* l' {$ ^5 U
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.( f1 x5 a* [( |( V( D
|